Jazz Pharmaceuticals PLC mainly meets criteria in the Momentum category. Result from 18 strategies checked.
View all strategies →Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
How comparable stocks in the same sector score in the StockScorer model.
| StockScorer score | ||
|---|---|---|
| JAZZ | Jazz Pharmaceuticals PLCthis page | |
| LLY | Eli Lilly and Company | High6.7 |
| LLY.TO | Eli Lilly and Company | Medium2.5 |
| JNJ | Johnson & Johnson | High6.7 |
| ABBV | AbbVie Inc | locked |
| UNH | UnitedHealth Group Incorporated | locked |
Jazz Pharmaceuticals PLC stock (JAZZ) is evaluated entirely rule-based in the StockScorer model. It currently reaches a StockScorer score of 2.5 out of 10, which corresponds to a medium match with the underlying strategies. The classification is deliberately neutral and is not a recommendation to buy, hold or sell.
The rating focuses on price momentum, meaning relative strength and trend versus the broader market. Overall, the stock passes through 18 different strategies, from quality through value to dividend approaches.
Jazz Pharmaceuticals PLC is assigned to the Healthcare sector. The sector classification makes it possible to compare the stock with peers from the same sector, for example in the peer comparison further up this page.
In healthcare, relevant criteria include earnings stability, research intensity and margin quality, among others. StockScorer compares many metrics against the sector average, so a stock is positioned not only in absolute terms but also relative to its sector.
StockScorer evaluates every stock entirely rule-based and without discretion. As a large-cap stock, Jazz Pharmaceuticals PLC is additionally measured against the stricter liquidity and balance-sheet standards of established market leaders. The criteria met across the 18 strategies produce the match shown per strategy as well as the summarising StockScorer score.
This makes it possible to see at a glance which investment styles a stock fits, without doing the calculation yourself. The decision remains yours. The values shown are purely informational and not investment advice.
Signed up in 30 seconds. Free, cancel anytime.
Not investment advice. The match shown reflects rule-based criteria and is not a recommendation to buy, hold or sell. Individual metrics are only visible after signing in, for licensing reasons.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.